Descripción de la empresa
MDxHealth SA operates as a commercial-stage precision diagnostics entity that delivers urologic testing solutions across the United States, Europe, and international markets. Its core offerings include Select mdx, a non-invasive urine test designed to measure the expression of two mRNA cancer-related biomarkers for prostate cancer detection. The company functions within the Healthcare sector, specifically targeting the Diagnostics & Research industry, which focuses on developing analytical tools and tests for medical conditions. With a market capitalization of $103.76M and trailing twelve-month revenue of $107.88M, the firm maintains a mid-tier valuation profile typical of specialized diagnostic providers. The revenue figure of $107.88M indicates that the company has achieved significant commercial traction despite operating without disclosed employee data, suggesting an efficient operational model or reliance on a lean workforce structure to generate nearly one hundred million dollars in annual sales.
Salud financiera
The company reported revenue of $107.88M over the trailing twelve months, yet this generated a net income of -$33,519,000 and an EBITDA of -$5,200,000. The substantial gap between the $107.88M in revenue and the -$33,519,000 in net income reveals a high cost structure where expenses significantly outweigh gross profits before interest and taxes. Free cash flow stands at -$2,822,250, indicating that the company is currently burning cash, which limits its immediate financial flexibility for capital expenditures or acquisitions without external financing. Gross margin is reported at 64.5%, demonstrating strong pricing power or low cost of goods sold relative to revenue, whereas the operating margin of -17.8% and profit margin of -31.1% highlight significant overhead costs that erode profitability at the operating level. The company holds $29.03M in cash against $86.60M in debt, resulting in a negative net cash position that suggests a leveraged balance sheet reliant on future cash generation or refinancing. Although the debt-to-equity ratio is not available, the current ratio of 1.08 indicates that current assets are just barely sufficient to cover current liabilities, reflecting tight short-term liquidity conditions. Return on Equity is calculated at -2440.4% and Return on Assets at -5.9%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Evaluación de valoración
The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed as -15.54, implying that the market prices in future earnings growth sufficient to turn the current losses into profits. The price-to-book ratio is -8.78, which indicates a valuation below book value often seen in distressed or turnaround situations rather than a premium over intrinsic book value. The price-to-sales ratio of 0.96 suggests the market values the company at slightly less than its annual revenue, while the EV/EBITDA of -31.47 further underscores the lack of current earnings power in the valuation model. The stock has a 52-week high of $5.33 and a 52-week low of $1.36, meaning the current price sits somewhere within this range depending on real-time market fluctuations, though the wide spread indicates significant volatility. The beta value is listed as -537543.56, an anomalous figure that technically implies extreme and inverted price volatility relative to the broader market, suggesting the stock moves with an erratic pattern that defies standard risk models. These alternative metrics provide a more complete picture than earnings multiples, highlighting that the market is valuing MDxHealth primarily on sales volume and potential rather than current profitability or traditional risk measures.
Growth & Income
Revenue growth year-over-year is 19.4%, while earnings growth is not available due to the company's current loss-making status. The absence of earnings growth data compared to the strong 19.4% revenue expansion implies that the company is prioritizing market share acquisition and scaling operations over immediate profit generation. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company reinvests all available cash flow back into research, development, and commercial expansion rather than distributing income to shareholders. This reinvestment strategy aligns with the profile of a commercial-stage company seeking to solidify its position in the urologic diagnostics market before achieving sustained profitability. The overall growth and income profile is characterized by double-digit revenue expansion coupled with significant cash consumption and no current shareholder returns.